MP65-08 THE ROLE OF TRANSURETHRAL RESECTION OF BLADDER TUMOR AFTER NEOADJUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER
Denise Asafu‐Adjei(Ann Arbor Center for Independent Living), Alon Z. Weizer(University of Michigan), Ted A. Skolarus(Chicago Department of Public Health), Todd M. Morgan(University of Michigan), Cheryl Lee(Agency for Science, Technology and Research), Maha Hussain(Northwestern University), Ajjai Alva(Michigan Medicine), Heather Crossley(Ann Arbor Center for Independent Living), James E. Montie(University of Michigan), Chang He(Ann Arbor Center for Independent Living), Khaled Hafez(University of Michigan), Jeffrey S. Montgomery(Ann Arbor Center for Independent Living), Brent K. Hollenbeck(University of Michigan), David C. Smith(University of Michigan), Stephen Dailey(Ann Arbor Center for Independent Living)
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k